Article

Lunai Bioworks Inc. outlined three revenue-generating segments: AI drug discovery, bio-defense, and immunotherapy in a shareholder letter. The Sacramento-based company has completed its AI platform and is negotiating partnerships with pharmaceutical firms.

Key collaborations include working with Supernus Pharmaceuticals on epilepsy and a new oncology project for colorectal cancer. The bio-defense segment includes Sentinel, Pathfinder, and CounterAct. Lunai's dendritic cell therapy showed promise in pancreatic tumor regression, with licensing discussions underway.